(Q83548587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Belma Ljutic

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Martina Ochs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Benjamin Messham

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Marin Ming

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Annie Dookie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Kevin Harper

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Salvador F Ausar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

27 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

2981-2988

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Pneumococcal Vaccination and Revaccination of Older Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Antibody response to pneumococcal vaccination in children younger than five years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Rapid pneumococcal evolution in response to clinical interventions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Serotype-specific problems associated with pneumococcal conjugate vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Streptococcus pneumoniae clonal complex 199: genetic diversity and tissue-specific virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Vaccine adjuvants: putting innate immunity to work

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Aluminum salts in vaccines--US perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Aluminum compounds used as adjuvants in vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Mechanisms of stimulation of the immune response by aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Mechanism of action of clinically approved adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Towards an understanding of the adjuvant action of aluminium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Preformulation studies--The next advance in aluminum adjuvant-containing vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Measuring the surface area of aluminum hydroxide adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Overcharging in colloids: beyond the Poisson-Boltzmann approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

[Principal comments on active vaccination against poliomyelitis.]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

The Influence of Various Adjuvants on the Metabolism of Phospholipids in Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.02.038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381074%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference